GSE182680 GSE182683 dexamethasone 5 v 8 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE182680_GSE182683_dexamethasone_5_v_8_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE182680_GSE182683_dexamethasone_5_v_8_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE182680_GSE182683_dexamethasone_5_v_8_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE182680_GSE182683_dexamethasone_5_v_8_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

H3 clustered histone 7

Gene

family with sequence similarity 106 member A

Gene

small nucleolar RNA host gene 1

Gene

growth arrest specific 5

Gene

small nucleolar RNA host gene 3

Gene

ZNFX1 antisense RNA 1

Gene

multidrug resistance-related protein

Gene

small nucleolar RNA host gene 7

Gene

deleted in lymphocytic leukemia 1

Gene

H3 clustered histone 10

  • Gene

    H3 clustered histone 7


  • Gene

    family with sequence similarity 106 member A


  • Gene

    small nucleolar RNA host gene 1


  • Gene

    growth arrest specific 5


  • Gene

    small nucleolar RNA host gene 3


  • Gene

    ZNFX1 antisense RNA 1


  • Gene

    multidrug resistance-related protein


  • Gene

    small nucleolar RNA host gene 7


  • Gene

    deleted in lymphocytic leukemia 1


  • Gene

    H3 clustered histone 10

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.